Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

TitleProstate stem cell antigen: a cell surface marker overexpressed in prostate cancer.
Publication TypeJournal Article
Year of Publication1998
AuthorsReiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON
JournalProc Natl Acad Sci U S A
Date Published1998 Feb 17
KeywordsAmino Acid Sequence, Antigens, Neoplasm, Antigens, Surface, Chromosome Mapping, Chromosomes, Human, Pair 8, Cloning, Molecular, Gene Expression Regulation, Neoplastic, Glycosylphosphatidylinositols, GPI-Linked Proteins, Humans, Male, Membrane Glycoproteins, Molecular Sequence Data, Neoplasm Proteins, Neoplastic Stem Cells, Prostate, Prostatic Neoplasms, RNA, Messenger

The identification of cell surface antigens is critical to the development of new diagnostic and therapeutic modalities for the management of prostate cancer. Prostate stem cell antigen (PSCA) is a prostate-specific gene with 30% homology to stem cell antigen 2, a member of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens. PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites. PSCA mRNA expression is prostate-specific in normal male tissues and is highly up-regulated in both androgen-dependent and -independent prostate cancer xenografts. In situ mRNA analysis localizes PSCA expression in normal prostate to the basal cell epithelium, the putative stem cell compartment of the prostate. There is moderate to strong PSCA expression in 111 of 126 (88%) prostate cancer specimens examined by in situ analysis, including high-grade prostatic intraepithelial neoplasia and androgen-dependent and androgen-independent tumors. Flow cytometric analysis demonstrates that PSCA is expressed predominantly on the cell surface and is anchored by a GPI linkage. Fluorescent in situ hybridization analysis localizes the PSCA gene to chromosome 8q24.2, a region of allelic gain in more than 80% of prostate cancers. A mouse homologue with 70% amino acid identity and similar genomic organization to human PSCA has also been identified. These results support PSCA as a target for prostate cancer diagnosis and therapy.

Alternate JournalProc Natl Acad Sci U S A
PubMed ID9465086
PubMed Central IDPMC19171
Grant ListP01 CA040046 / CA / NCI NIH HHS / United States
CA40046 / CA / NCI NIH HHS / United States
K08 CA74169 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700